Group 1 - The core viewpoint of the news is that Jiuyuan Gene has received acceptance for its clinical trial application for the innovative drug JY54 injection, aimed at weight management in Phase I studies [1] - JY54 injection is a next-generation weight loss therapy that operates through a mechanism similar to insulin, providing multiple metabolic regulation effects [1] - The product is positioned to complement existing GLP-1 products, highlighting the company's strategic extension in the field of metabolic diseases [1] Group 2 - In the recent stock performance, Jiuyuan Gene's share price experienced a fluctuation, reaching a high of 10.35 HKD on February 10 and a low of 9.40 HKD on February 13, with a total decline of 4.39% over the period [2] - Following the announcement, there was a significant increase in trading volume on February 10, with a turnover of 572.71 million HKD, but subsequent trading days saw a decrease in volume [2] - The company repurchased 26,000 shares at a cost of 255,300 HKD on February 12, indicating limited scale in its buyback activity [2]
九源基因创新药临床试验申请获受理 股价冲高回落
Jing Ji Guan Cha Wang·2026-02-13 11:03